Intracorporeal lithotripsy with the Swiss lithoclast

Giant urethral calculus in anterior urethral diverticulum: a case report

BACKGROUND

In this case report, giant calculus in the urethral diverticulum was found through ureteroscopy investigation, the pneumatic lithotripsy combined with ultrasound lithotripsy (PLCUL) was successfully performed to break down this rare and giant urethral calculus in the diverticulum without open surgery.

CASE PRESENTATION

A 82-year-old male presented to the urology department, complaining of frequent urination and dysuria. One giant, dark brown stone (6.5 × 6 × 5.5 cm) was revealed in the diverticulum of the anterior urethra using combination of local ultrasound, pelvic Computer Tomography (CT) and Magnetic Resonance Imaging (MRI). The stone was then successfully broken down via the PLCUL, and the emptied anterior urethral diverticulum was left untreated. In the 18 months' follow-up, no new calculus was found in urethral tract, anterior diverticula became gradually smaller, eventually disappeared.

CONCLUSION

In the treatment of giant calculus in the urethral diverticulum, this case report provides an effective method of lithotripsy in the clinical trials.

Clinical experience with the Swiss lithoclast master in treatment of bladder calculi

BACKGROUND AND PURPOSE

Bladder calculi account for 5% of urinary tract calculi in the Western world, and many different treatment modalities have been presented throughout the decades. We report our clinical experience using the Swiss LithoClast® Master (SLM).

MATERIALS AND METHODS

The SLM is a rigid, hand-held endourologic probe including a pneumatic lithotriptor and an ultrasonic lithotriptor. Attached to the ultrasonic modality is a suction system. The two lithotriptor modalities are controlled by a footswitch and can be activated separately or simultaneously. The SLM is used via a rigid endoscope. Indications for treatment were medical complaints such as hematuria, lower urinary tract symptoms, pain, recurrent urinary tract infections, recurrent bursts of balloon in indwelling catheters, and difficulties performing clean intermittent self-catheterization.

RESULTS

From August 1, 2009, to August 1, 2011, 27 patients were treated for bladder calculi (24 men). Five had a neurogenic voiding dysfunction, 3 had prostate cancer, and 19 had benign prostatic enlargement or detrusor muscle insufficiency. Median age was 74 years (range 45-86 years). Stone clearance was obtained in 26 (96%) patients. Stone burden was one or multiple bladder calculi. Median stone size of the largest stone in each patient was 20 (5-40) mm. Under the same anesthesia, two patients underwent a transurethral resection of the prostate because of a very large prostate. Median lithotripsy time was 60 (range 20-144) minutes. All patients were discharged within 24 hours.

CONCLUSION

The method described is a safe and quick method for endoscopic lithotripsy of bladder calculi rendering the patients stone free in the vast majority of cases. The procedure can be performed as day-case surgery.

Initial clinical evaluation of a new pneumatic intracorporeal lithotripter

OBJECTIVE

To test the clinical efficacy of the StoneBreaker (LMA Urology, Gland, Switzerland), a novel device which is much more compact and ergonomic than other current intracorporeal pneumatic lithotripters, and more powerful, generating contact pressures of up to 2.9 MPa, thereby enabling better pneumatic fragmentation and removal of stones during percutaneous nephrostolithotomy (PCNL), ureteroscopic stone fragmentation (USF) and vesical stone lithotripsy (VL).

PATIENTS AND METHODS

We prospectively evaluated 102 patients, comprising 49 PCNLs, 48 USFs and 5 VLs, treated using the StoneBreaker. The stone size, position, number of shocks required to fragment the stone to effect complete clearance, and degree of retropulsion were documented in each case; any evidence of urothelial trauma was noted.

RESULTS

All stones were satisfactorily fragmented and all patients rendered stone-free. Very few shocks were required, and documented retropulsion was minor. There was no evidence of consequential urothelial trauma at the end of any procedure.

CONCLUSION

The StoneBreaker appears to be a safe, effective, robust and compact device for intracorporeal lithotripsy.

In-situ holmium laser lithotripsy for impacted urethral calculi

BACKGROUND AND PURPOSE

Urethral calculi usually present as acute retention of urine. The issues in this rare clinical problem are its emergency management scenario, small urethral caliber, and long-term risk of stricture formation. In this retrospective study, the positive experience with the safety and efficacy of holmiumlaser lithotripsy for ureteral calculi was applied to the management of urethral calculi, and the initial results were analyzed.

PATIENTS AND METHODS

From October 1999 to June 2003, 42 patients presented with symptomatic urethral calculi. Under anesthesia, an attempt was made to push the calculus back in the bladder using lidocaine jelly. In 18 patients in whom this attempt failed, in-situ intracorporeal holmium lasertripsy was performed under cystourethroscopic guidance.

RESULTS

All the patients were rendered stone free after a single endoscopic procedure. There were no intraoperative or postoperative complications. At a mean follow-up of 22.28 months (range 5-35 months), 17 of the patients having lasertripsy were asymptomatic with no evidence of development of urethral stricture.

CONCLUSION

Intracorporeal intraurethral holmium lasertripsy is a feasible, safe, and effective minimally invasive alternative for the treatment of impacted male urethral calculi.

Treatment of Urolithiasis with Ureterocele: 5 Years of Experience (1998–2003)

To assess efficacy of Extracorporeal Shock Wave Lithotripsy (ESWL) about treatment of urolithiasis with ureterocele.

Materials and Methods

From January 1998 to July 2003, we have treated 6 adult patients (4 women and 2 men) with urolithiasis linked to ureterocele with mean age 35.8 years (range between 24–49 years). The patients showed dysuria, and pain during advanced stage of miction. The diagnosis of ureterocele was based by ultrasound and intravenous urography. The ureterocele appeared monolateral in 5 patients and bilateral in 1 patient. The stone is been treated with Extracorporeal Shock Wave Lithotripsy (4000 shocks; 9Kj), in mean 2 applications for patient.

Results

In 4 patients we have assessed breaking stone with expulsion of chips. In 2 patients, after treatment with ESWL, we have proceeded to extract the stone by endoscopic view, by small cut (“smile cut”) on ureterocele wall. Reflux was not present in these 2 patients after smile cut.

Conclusions

In patients with urolithiasis and ureterocele is recommended to perform a treatment of ESWL, that proved to be effectiveness, allowed by patients and without collateral effects.

Utility of the lithoclast in the treatment of upper, middle and lower ureteric calculi

OBJECTIVE

The aim of this study was to evaluate the utility and efficacy of lithoclast in the treatment of upper, middle and lower ureteric calculi.

PATIENTS AND METHODS

Over a period of 6 1/2 years, we have treated 529 ureteric stones which failed to pass spontaneously within a 2-week period. Patients were evaluated for number, site, size and laterality of stones. Patients with ureteroscopy failure were excluded from the study. Once the stone(s) was (were) localised with the ureteroscope, it (they) was (were) treated with the Swiss lithoclast.

RESULTS

Complete fragmentation was achieved in 99% of cases with lower, 97% with mid and 71% with upper ureteric calculi, respectively. The lithotripsy time was only 8.6 minutes for stones < or =1 cm and 14.8 minutes for stones ranging from 1.1 to 2.0 cm. Completely fragmented stones cleared spontaneously within two weeks in 98% of cases and all patients were free of calculi one month after the procedure. Retreatment with the lithoclast was required in six patients for large residual fragments. The mean hospital stay was 1.2 days. Complications were encountered in 6.8% of cases and were managed conservatively.

CONCLUSIONS

Pneumatic lithotripsy is an excellent form of treatment for lower and mid-ureteric calculi. It is a very reliable, highly effective, rapid and safe procedure.

Combining Lithoclast and ultrasound power in one device for percutaneous nephrolithotomy: in vitro results of a novel and highly effective technology

OBJECTIVES

A new device for percutaneous nephrolithotomy, combining Lithoclast (LC) and ultrasound (US) lithotripsy, was developed. Under standardized in vitro conditions, we evaluated the efficacy of the new technique using artificial stones. Combined application of pneumatic and US lithotripsy was compared with each of the two components alone.

METHODS

Five different artificial stones of defined hardness were used. Disintegration was performed under defined pressure in a water bath. The time until the first fragmentation and until complete disintegration to fragments of 2 mm or smaller was measured for LC and US alone and for combined lithotripsy. Furthermore, the disintegrated partition after 1 minute and time until 50% disintegration of each stone was determined.

RESULTS

With regard to first fragmentation and complete disintegration, LC and US combination showed superior efficacy. First fragmentation was achieved 25 to 200 times faster and complete disintegration in a range of 11 to 15 minutes. No complete disintegration was possible by LC and US alone within a time limit of 20 minutes. The disintegrated stone mass after 1 minute was 1.5 to 4 times larger in combined lithotripsy and the 50% disintegration time was 30% to 50% compared with LC or US alone. No technical defects occurred.

CONCLUSIONS

Combining LC and US in one device for percutaneous nephrolithotomy shows promising in vitro results in an artificial stone model. It seems to provide superior efficacy in the disintegration parameters important for clinical practice.

Experimental studies and first clinical experience with a new Lithoclast and ultrasound combination for lithotripsy

OBJECTIVES

A new lithotriptor for intracorporeal lithotripsy was developed combining the two most effective lithotriptors. A combination of the mechanically driven Lithoclast Master and a new ultrasonic device was constructed. Efficacy was tested in standardized model stones and in patient treatment.

MATERIAL

The new lithotriptor is composed of a Lithoclast Master and an ultrasonic device (EMS, Nyon, Switzerland). The 1.0 mm Lithoclast probe is advanced off-center through the hollow 3.3 mm ultrasonic probe and protrudes about 1 mm. Five different artificial stones of defined hardness and density were used as model stones for disintegration. Time until first fragmentation and complete fragmentation (particles smaller than 2.2 mm to fit through the ultrasonic probe), percent disintegration after 1 min and time until 50% disintegration were determined for the new device as well as lithoclast and ultrasound alone. A total of 68 patients were treated by percutaneous nephrolitholapaxy (PNL) with the new device from February 1999 to August 2001. Lithotripsy was performed after fluoroscopically guided puncture of the lower calix and dilatation of the nephrostomy tract with coaxial bougies. Thirty-five patients had complete and 33 patients partial staghorn calculi.

RESULTS

First fragmentation was reached 25-200 times faster with the combination as with either mode alone. Disintegrated stone mass after 1 min was 1.5-4 times larger in combined lithotripsy and 50% disintegration time 30-50% shorter. Clinically, complete stone free rate (KUB and ultrasound) was 66% after the first PNL. Sixteen out of 68 patients had a second look PNL with an overall stone free rate of 89.7% by dismission. Stone composition was calcium-oxalate-monohydrate in 13%, Ca-ox-monohydrate/uric acid in 35%, apatite in 20% and cystine in 11%.

CONCLUSION

In in vitro experiments and clinically the new lithotriptor provides easy handling and high effectivity in fragmentation of all stones regardless of their composition.

Percutaneous suprapubic cystolithotripsy for treatment of large bladder calculi

BACKGROUND AND PURPOSE

The treatment options available for managing bladder calculi include transurethral cystolithotripsy, open cystolithotomy, and shockwave lithotripsy. For larger calculi, transurethral treatment can be time consuming, and the manipulation has the potential to cause urethral injury. Percutaneous suprapubic cystolithotripsy represents another treatment option for bladder calculi which is effective and minimally invasive.

PATIENTS AND METHODS

Fifteen patients had bladder calculi treated with percutaneous cystolithotripsy over a 3-year period. The mean stone size was 39 mm (range 10-64 mm). Stones were single in seven patients and multiple in eight patients. The indications for cystolithotripsy were stone size >3 cm, multiple stones >1 cm, and inability to perform transurethral cystolithotripsy because of patient anatomy. Percutaneous suprapubic cystolithotripsy was done through either a 30F or a 36F cystotomy tract. Fragmentation and removal was performed with a 26F rigid nephroscope and the pneumatic Swiss Lithoclast. Suprapubic and urethral catheters were placed postoperatively in all patients.

RESULTS

Each patient was cleared of the stone burden with a single procedure, and there were no major complications. The mean duration of suprapubic catheterization was 2.6 (range 1-5) days.

CONCLUSION

Percutaneous suprapubic cystolithotripsy is an effective and safe technique for treating large bladder calculi. It is minimally invasive, avoids urethral injury, and, in combination with the pneumatic Swiss Lithoclast, can be used to fragment and remove large and hard bladder calculi.

The role of ureteral stent placement in the prevention of Steinstrasse

BACKGROUND AND OBJECTIVE

Steinstrasse constitutes a potentially serious complication of extracorporeal shock-wave lithotripsy (SWL). Ureteral stent placement has been used to prevent Steinstrasse after fragmentation of larger stones. However, particularly more recently, its preventive efficacy has been questioned. The aim of this study therefore was to analyze the role of ureteral stent placement in the prevention of Steinstrasse.

METHODS

We analyzed data of 1087 patients who had been treated with a Wolf Piezolith 2300 in the General Infirmary in Leeds/UK for stones ranging from 10 to 95 mm in diameter.

RESULTS

The incidence of Steinstrasse was 6.3%. The likelihood was significantly correlated with the stone size and was significantly less in patients with stones >20 mm if a stent had been inserted prior to SWL. Moreover, in these patients, the risk of acute clinical symptoms in the event of Steinstrasse was greatly reduced, and the treatment could be continued safely in the majority of cases (86%). Treatments of the Steinstrasse itself with SWL resulted in its clearance in most of the cases (78%). It was always possible to clear even extended persistent Steinstrasse by laser lithotripsy.

CONCLUSION

These results provide a clear indication for the pre-SWL insertion of a ureteral stent in patients with stones >20 mm in diameter. In the event of Steinstrasse, SWL of the collection should be tried before more invasive endourologic procedures are considered.

Holmium: YAG lasertripsy for ureteric calculi: an experience of 300 procedures

OBJECTIVE

To assess the success of holmium:YAG lasertripsy in the management of ureteric calculi and to audit the complications of the procedure, with special reference to strictures in the ureter.

PATIENTS AND METHODS

A total of 300 ureteroscopic laser procedures were carried out on 265 patients (204 male and 61 female, median age 51 years, range 2-95) with ureteric calculi. At ureteroscopy, the calculi were present in the upper ureter in 44%, mid-ureter in 37% and lower ureter in 19% of patients; most calculi were > 5 mm. A 7.5 F Wolf semi-rigid ureteroscope was used and the holmium:YAG laser energy delivered using the Sharplan ML210 device at 0.8-1.0 J/pulse. The patients were followed up at approximately 6 weeks with limited intravenous urography or ultrasonography to assess clearance and the incidence of strictures.

RESULTS

Stones were completely cleared in 90% of the patients, with the best results in the lower and mid-ureter (97% and 96%, respectively) followed by the upper ureter (89%). Alternative procedures were required in only 17 (7%) patients; extracorporeal shock-wave lithotripsy in 13, percutaneous nephrolithotomy in two and open pyelolithotomy in two patients. Complications with ureteric perforation in 11 patients, including laparotomy for peritonitis in one, serious sepsis in two and strictures in 10 patients. Strictures were more common in association with impacted calculi in the upper ureter early in the series.

CONCLUSIONS

Holmium:YAG lasertripsy is a highly effective treatment for ureteric calculi, with strictures related to the treatment of difficult upper ureteric calculi.

Ureteroscopic lithoclast lithotripsy: a cost-effective option

Seventy-four consecutive cases of ureteral stones listed for ureteroscopic lithotripsy were studied prospectively. In all cases, the Wolf 7.5F or 9F ureteroscope was used in conjunction with the Swiss Lithoclast system. Dormia baskets were employed on four occasions to prevent forward propulsion of fragments. Ureteroscopic access to the stones was successful in 70 patients (95%). Lithoclast lithotripsy was successfully applied in 68 patients (92%), with complete fragmentation noted in 62 patients (91%), one requiring two sessions. The 6-week stone-free rate was 96% for these patients. Five patients with partial fragmentation had successful adjuvant SWL. The overall successful fragmentation rate was thus 84% (62 of 74) and 91% (67 of 74) in combination with adjuvant SWL. Cost analysis indicated a three-fold advantage for the Lithoclast over Candela lasertripsy. Ureteroscopic Lithoclast lithotripsy is a cost-effective treatment modality for ureteral stones.

Combination of pneumatic lithotripsy and transurethral prostatectomy in bladder stones with benign prostatic hyperplasia

We present our experience with combined pneumatic lithotripsy and transurethral resection of the prostate (TURP) in 52 patients with bladder stone(s) and benign prostatic hyperplasia (BPH). All stones were fragmented with the pneumatic Swiss Lithoclast. Pneumatic lithotripsy and evacuation caused a mean increase of 16 minutes in operating time. No complications, other than mild hematuria, were observed intraoperatively because of pneumatic lithotripsy. We observed early and long-term complications related to the procedure in 13% of patients. The average hospital stay was 3.2 days. The combination of pneumatic lithotripsy and TURP appears to be an effective, safe, and economical treatment method for patients with bladder stone(s) and BPH.

Intracorporeal pneumatic lithotripsy for ureteral and vesical calculi

To evaluate the effectiveness of pneumatic lithotripsy, 92 patients with 98 lower or mid-ureteric calculi and 8 with vesical calculi were treated with pneumatic lithotripsy (Swiss Lithoclast) under spinal anaesthesia. Successful stone fragmentation was achieved in 96 patients. In two patients their stones migrated to the upper ureter and renal pelvis during the procedure and so they were referred for extra corporeal shock wave lithotripsy. Total ureteral avulsion occurred in one patient and in another case attempts to dilate the stenotic ureteral orifice failed. In both cases, ureterolithotomy and ureteral reimplantation were performed. Pneumatic lithotripsy is found to be an easy, reliable and cost-effective method of endoscopic lithotripsy.

Intracorporeal lithotripsy with the Swiss Lithoclast

BACKGROUND

In addition to currently available modalities of intracorporeal lithotripsy (ultrasonic, electrohydraulic, and laser), a new ballistic lithotriptor known as the Swiss Lithoclast has recently gained attention. This study reports our experience with the Swiss Lithoclast in the endoscopic management of urinary calculi.

METHODS

A total of 51 patients with urinary calculi were treated with the Swiss Lithoclast; one patient with a renal calculus, 28 with ureteral calculi, and 22 with lower urinary tract (bladder, urethra and Kock pouch) calculi.

RESULTS

The Lithoclast successfully fragmented 94% of the calculi, independent of stone composition. Complete failure of fragmentation was not encountered. In six of the 10 upper ureteral calculi, stone fragments were pushed up into the calyces. Adjunctive extracorporeal shock wave lithotripsy for residual fragments was performed in six cases. The stone-free rate at one and three months was 84% and 88%, respectively. There were no intraoperative or long-term complications directly related to the use of this device.

CONCLUSION

The Swiss Lithoclast is a safe and effective means of intracorporeal lithotripsy. Although suitable for mid and lower ureteral stones, the device has a risk of stone push-up in patients with upper ureteral stones.